Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients will have measurable disseminated colorectal cancer that is incurable by surgery
Patients will have had tumor progression following standard combination front-line or second-line chemotherapy.
CRC patients who have relapsed or recurrent disease within six months after completing adjuvant or neoadjuvant chemotherapy
You may not be if
Previous treatment with PARP inhibitors, including olaparib.
Patients with symptomatic, uncontrolled brain metastases.
Patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 4 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used).
Patients who are unable to swallow orally administered medication.
Clareo Health | Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
